What does a low IgA level on serum protein electrophoresis with immunofixation (IFE) indicate?

What Does Low IgA Mean on Serum Protein Electrophoresis with Immunofixation?

Low IgA on serum protein electrophoresis with immunofixation requires immediate assessment of the absolute IgA level, clinical context, and medication history to distinguish between selective IgA deficiency (SIGAD), secondary causes, or progression to more severe immunodeficiency.

Diagnostic Thresholds and Definitions

The interpretation of low IgA depends critically on the absolute value:

• **IgA <7 mg/dL with normal IgG and IgM** in patients >4 years old defines Selective IgA Deficiency (SIGAD) after excluding other causes of hypogammaglobulinemia 1
• IgA between 7 mg/dL and lower limit of normal should NOT be diagnosed as IgA deficiency, as there are no consistently identified clinical associations in this range 1
• Most clinical laboratories cannot measure IgA levels below 7 mg/dL, though specialty laboratories can distinguish truly absent IgA (one-third of cases) from very low but detectable levels (two-thirds of cases) 1

Primary Differential Diagnosis

1. Selective IgA Deficiency (SIGAD)

The most common primary immunodeficiency, affecting approximately 1 in 300-700 white individuals in the United States (much rarer in Asian populations at 1:18,000) 1. Key features include:

• Most patients are asymptomatic (the majority have no clinical problems) 1

• When symptomatic, manifestations include:

  • Recurrent sinopulmonary infections
  • Atopy and allergic disease
  • Autoimmune diseases
  • Celiac disease
  • Gastrointestinal infections
  • Increased malignancy risk 1

• Family history is present in 20-25% of cases (either SIGAD or CVID in relatives) 1

• Impaired specific antibody responses to pneumococcal polysaccharide antigens may occur, though correlation with infection history is inconsistent 1

2. Drug-Induced IgA Deficiency

Critical pitfall: Always obtain a thorough medication history, as SIGAD can be acquired and potentially reversible with drug cessation 1. Causative medications include:

• Antiepileptic drugs: phenytoin, carbamazepine, valproic acid, zonisamide
• Disease-modifying agents: sulfasalazine, gold, penicillamine, hydroxychloroquine
• NSAIDs 1

3. Evolution to Common Variable Immunodeficiency (CVID)

Some patients with SIGAD will develop CVID later in life 1. This represents progression to more severe immunodeficiency and requires long-term monitoring.

4. Combined IgA and IgG Subclass Deficiency

Low IgA may occur with low IgG2 and/or IgG4 levels 1. In one study, IgA deficiency was found in 9.3% of patients with respiratory infections, IgG subclass deficiency in 8.4%, but combined deficiency in only 1.4% 1. The functional significance of this combination is not well understood 1.

Clinical Management Algorithm

Step 1: Confirm the Finding

• Repeat measurement to confirm low IgA level
• Measure total IgG, IgM, and serum albumin/total protein to exclude secondary hypogammaglobulinemia 1

Step 2: Medication Review

• Review all current and recent medications
• Consider trial discontinuation of potentially causative drugs if clinically appropriate 1

Step 3: Assess Functional Antibody Production

• Measure specific antibody responses to protein and polysaccharide antigens (pneumococcal vaccine response) 1
• This helps determine clinical significance and guide management

Step 4: Risk Stratification and Monitoring

For asymptomatic patients:

• Long-term vigilance with periodic monitoring for development of complications 1
• No specific treatment required

For symptomatic patients with recurrent infections:

• Aggressive antimicrobial therapy for acute infections 1
• Prophylactic antibiotics for patients with frequent infections 1
• Aggressive treatment of atopic disease if present, as allergic inflammation predisposes to respiratory infections 1
• IVIG therapy is controversial and rarely beneficial in SIGAD; consider only in patients with recurrent infections negatively affecting quality of life when aggressive antibiotics fail or cause intolerable side effects 1

Step 5: Special Precautions

Blood product administration: Patients with IgA deficiency may develop anti-IgA antibodies, creating theoretical risk for anaphylactic reactions to blood products. While the actual risk to individual patients is likely small, some centers use IgA-deficient blood products or wash cells before transfusion 1.

Important Caveats

• Age consideration: Do not diagnose SIGAD before age 4 years, as immunoglobulin levels are still developing 1
• Masked monoclonal proteins: In the context of hypogammaglobulinemia, immunofixation may reveal monoclonal components not visible on standard protein electrophoresis alone—nearly 1 in 4 patients with hypogammaglobulinemia have detectable monoclonal components on IFE 2
• IVIG interference: If the patient is receiving IVIG therapy, this can obscure small monoclonal proteins on electrophoresis 3

Long-Term Monitoring

Patients with confirmed SIGAD require ongoing surveillance for:

• Development of CVID (progressive immunodeficiency)
• Autoimmune complications
• Celiac disease
• Malignancy
• Chronic lung disease from recurrent infections 1